SCHEMBL4055227

SCHEMBL4055227

CC(=O)Nc1ccc(-n2nc(Br)c3ccccc3c2=O)cc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.60
MAPT P10636 3/20 0.60
ADORA3 P0DMS8 3/20 0.51
NPC1 O15118 4/20 0.50
RAB9A P51151 4/20 0.50
SCN2A Q99250 1/20 0.48
ALDH1A1 P00352 1/20 0.48
PTGS2 P35354 2/20 0.47
HTT P42858 2/20 0.47
ABCB1 P08183 2/20 0.47
TSHR P16473 1/20 0.46
POLB P06746 2/20 0.46
PKM P14618 1/20 0.45
MEN1 O00255 3/20 0.44
KMT2A Q03164 3/20 0.44
USP2 O75604 1/20 0.44
BLM P54132 1/20 0.44
CYP3A4 P08684 1/20 0.44
CYP2C9 P11712 1/20 0.44
HPGD P15428 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4069247 0.79 HTT (0.53) ADORA3NPC1RAB9AALDH1A1HTT
SCHEMBL4066956 0.79 AURKA (0.62) KDM4EMAPTALDH1A1MEN1KMT2A
SCHEMBL4060721 0.78 BCAT1 (0.58) MAPTADORA3NPC1RAB9AALDH1A1
SCHEMBL4060936 0.78 HTT (0.70) ADORA3NPC1RAB9AHTTPOLB
SCHEMBL4063456 0.76 RAB9A (0.55) KDM4EADORA3NPC1RAB9AALDH1A1
SCHEMBL4055423 0.75 RAB9A (0.55) KDM4EADORA3NPC1RAB9AALDH1A1
SCHEMBL4059604 0.75 RAB9A (0.55) KDM4ENPC1RAB9AALDH1A1HTT
SCHEMBL4067019 0.75 NPC1 (0.46) KDM4EADORA3NPC1RAB9AALDH1A1
SCHEMBL4712003 0.75 HTT (0.62) ADORA3NPC1RAB9AALDH1A1HTT
SCHEMBL20916990 0.75 PTGS2 (0.67) KDM4EMAPTNPC1RAB9AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101027290-B 2, 3-phthalazinone derivatives as AURORA-a kinase inhibitors HOFFMANN LA ROCHE 2010-05-12 CN disclosed
EP-1794148-B1 NOVEL PHTHALAZINONE DERIVATIVES, AS AURORA-A KINASE INHIBITORS HOFFMANN LA ROCHE (CH) 2009-04-15 EP disclosed
CN-101405001-A Methods of inhibiting BTK and SYK protein kinases HOFFMANN LA ROCHE (CH) 2009-04-08 CN disclosed
US-7501410-B2 Methods of inhibiting BTK and SYK protein kinases ROCHE PALO ALTO LLC (US) 2009-03-10 US disclosed
US-20070219195-A1 e.g. 4-(5-Methyl-2H-pyrazole-3-ylamino)-phenyl-2H-phthalazin-1-one2-Phenyl-2,3-dihydro-phthalazine-1,4-dione; tyrosine kinase inhibitor; antiinflammatory agent; asthma, rheumatoid arthritis, systemic lupus erythematosus or multiple sclerosis ROCHE PALO ALTO LLC 2007-09-20 US disclosed
CN-101027290-A Novel 2,3-phthalazinone derivatives, as AURORA-A kinase inhibitors HOFFMANN LA ROCHE (CH) 2007-08-29 CN disclosed
US-7226923-B2 Phthalazinone derivatives HOFFMAN-LA ROCHE INC. (US) 2007-06-05 US disclosed
US-20060089359-A1 Phthalazinone derivatives F. HOFFMANN-LA ROCHE AG (CH) 2006-04-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060089359-A1 Phthalazinone derivatives SDHA, SDHB, CYP3A5 KDM4E 3447/4885MAPT 1732/4885ADORA3 4111/4885
US-20070219195-A1 e.g. 4-(5-Methyl-2H-pyrazole-3-ylamino)-phenyl-2H-phthalazin-1-one2-Phenyl-2,3-dihydro-phthalazine-1,4-dione; tyrosine kinase inhibitor; antiinflammatory agent; asthma, rheumatoid arthritis, systemic lupus erythematosus or multiple sclerosis SYK, BTK, LCK KDM4E 217/4885MAPT 2762/4885ADORA3 4647/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.